<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Larotrectinib: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Larotrectinib: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Larotrectinib: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="119755" href="/d/html/119755.html" rel="external">see "Larotrectinib: Drug information"</a> and <a class="drug drug_patient" data-topicid="119860" href="/d/html/119860.html" rel="external">see "Larotrectinib: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F52187112"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Vitrakvi</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F53721526"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Vitrakvi</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F52181433"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antineoplastic Agent, Tropomyosin Receptor Kinase (TRK) Inhibitor</span></li></ul></div>
<div class="block dop drugH1Div" id="F52812472"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> Dosing presented as a fixed mg dose, and as mg/<b>m<sup>2</sup></b>; use caution.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e3ba2298-d7a6-4552-97d8-f1cd836e247a">Solid tumor with presence of neurotrophic receptor tyrosine kinase gene fusion</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Solid tumor (unresectable or metastatic) with presence of neurotrophic receptor tyrosine kinase (<i>NTRK</i>) gene fusion:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">BSA &lt;1 m<sup>2</sup>: Oral: 100 mg/<b>m<sup>2</sup></b>/dose twice daily; continue until disease progression or unacceptable toxicity.</p>
<p style="text-indent:-2em;margin-left:6em;">BSA ≥1 m<sup>2</sup>: Oral: 100 mg twice daily; continue until disease progression or unacceptable toxicity.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosing adjustment for toxicity:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Oral:</p>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<caption style="text-align:left;">
<b>Dosage Adjustments for Larotrectinib Toxicity in Infants, Children, and Adolescents</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;">
<b>BSA</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>First dose reduction</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Second dose reduction</b></p></th>
<th align="left">
<p style="text-indent:0em;">Third dose reduction<sup>a</sup></p></th></tr></thead>
<tfoot valign="top">
<tr>
<td align="left" colspan="4">
<p style="text-indent:0em;">
<sup>a</sup> Permanently discontinue if unable to tolerate larotrectinib after 3 dose reductions.</p></td></tr>
<tr>
<td align="left" colspan="4">
<p style="text-indent:0em;">
<sup>b</sup> Maintain dose at 25 mg/<b>m<sup>2</sup></b> twice daily even if BSA increases to ≥1 m<sup>2</sup> during treatment.</p></td></tr></tfoot>
<tbody valign="top">
<tr>
<td align="left">
<p style="text-indent:0em;">BSA &lt;1 m<sup>2</sup></p></td>
<td align="left">
<p style="text-indent:0em;">75 mg/<b>m<sup>2</sup></b> twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">50 mg/<b>m<sup>2</sup></b> twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">25 mg/<b>m<sup>2</sup></b> twice daily<sup>b</sup></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">BSA ≥1 m<sup>2</sup></p></td>
<td align="left">
<p style="text-indent:0em;">75 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">50 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">100 mg once daily</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">Grade 3 or 4 adverse reactions: Withhold treatment until adverse reaction resolves or improves to baseline or ≤ grade 1. Resume with appropriate dosage modification if resolution occurs within 4 weeks. Permanently discontinue if not resolved within 4 weeks or if unable to tolerate after 3 dose reductions.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F52181441"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">No dosage adjustment is necessary for any degree of renal impairment.</p></div>
<div class="block dohp drugH1Div" id="F52181442"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Baseline hepatic impairment:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Mild impairment: No dosage adjustment is necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate to severe impairment: Reduce initial dose by 50%.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hepatotoxicity during treatment:</i></p>
<p style="text-indent:-2em;margin-left:4em;">ALT or AST ≥5 × ULN with bilirubin ≤2 × ULN: Withhold larotrectinib until recovery to ≤ grade 1 or baseline; resume at the next lower dosage level. Discontinue permanently if grade 4 AST and/or ALT elevation occurs after resuming larotrectinib.</p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<caption style="text-align:left;">
<b>Dosage Adjustments for Larotrectinib Toxicity in Infants, Children, and Adolescents</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;">
<b>BSA</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>First dose reduction</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Second dose reduction</b></p></th>
<th align="left">
<p style="text-indent:0em;">Third dose reduction<sup>a</sup></p></th></tr></thead>
<tfoot valign="top">
<tr>
<td align="left" colspan="4">
<p style="text-indent:0em;">
<sup>a</sup> Permanently discontinue if unable to tolerate larotrectinib after 3 dose reductions.</p></td></tr>
<tr>
<td align="left" colspan="4">
<p style="text-indent:0em;">
<sup>b</sup> Maintain dose at 25 mg/<b>m<sup>2</sup></b> twice daily even if BSA increases to ≥1 m<sup>2</sup> during treatment.</p></td></tr></tfoot>
<tbody valign="top">
<tr>
<td align="left">
<p style="text-indent:0em;">BSA &lt;1 m<sup>2</sup></p></td>
<td align="left">
<p style="text-indent:0em;">75 mg/<b>m<sup>2</sup></b> twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">50 mg/<b>m<sup>2</sup></b> twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">25 mg/<b>m<sup>2</sup></b> twice daily<sup>b</sup></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">BSA ≥1 m<sup>2</sup></p></td>
<td align="left">
<p style="text-indent:0em;">75 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">50 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;">100 mg once daily</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">ALT or AST &gt;3 × ULN with bilirubin &gt;2 × ULN (in absence of other causes): Discontinue larotrectinib permanently.</p></div>
<div class="block doa drugH1Div" id="F52187312"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="119755" href="/d/html/119755.html" rel="external">see "Larotrectinib: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="03b5a007-021e-4637-9774-4b09d1118058">Solid tumors</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Solid tumors (with neurotrophic tyrosine receptor kinase [NTRK] gene fusion):</b> Oral: 100 mg twice daily until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29466156']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29466156'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed dose: </i>Do not make up the missed dose within 6 hours of the next scheduled dose. If vomiting occurs, take the next dose at the scheduled time.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F52187315"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block doha drugH1Div" id="F52187316"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hepatic impairment prior to treatment initiation:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Mild impairment (Child-Pugh class A): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate to severe impairment (Child-Pugh classes B and C): Reduce the initial larotrectinib dose by 50%.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hepatotoxicity during treatment: </i></p>
<p style="text-indent:-2em;margin-left:4em;">ALT or AST ≥5 times ULN with bilirubin ≤2 times ULN: Withhold larotrectinib until recovery to ≤ grade 1 or baseline; resume at the next lower dosage level. Discontinue permanently if grade 4 AST and/or ALT elevation occurs after resuming larotrectinib.</p>
<p style="text-indent:-2em;margin-left:4em;">ALT or AST &gt;3 times ULN with bilirubin &gt;2 times ULN (in absence of other causes): Discontinue larotrectinib permanently.</p></div>
<div class="block adr drugH1Div" id="F52181449"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adult and pediatric patients.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema (19%; includes facial edema, genital edema)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatological: Skin rash (19%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypoalbuminemia (36%), hypocalcemia (25%), weight gain (14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (21%), constipation (27%), decreased appetite (12%), diarrhea (27%; grades 3/4: 1%), nausea (25%; grades 3/4: &lt;1%), vomiting (25%; grades 3/4: &lt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (42%; grades 3/4: 10%), leukopenia (28%; grades 3/4: 2%), lymphopenia (22%; grades 3/4: 6%), neutropenia (36%; grades 3/4: 14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (45%), increased serum alkaline phosphatase (34%), increased serum aspartate aminotransferase (52%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Cognitive dysfunction (11%; including amnesia, aphasia, hallucination, mental status changes), dizziness (27%), fatigue (36%; including asthenia), headache (15%), mood disorder (14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Musculoskeletal pain (42%; includes arthralgia, back pain, limb pain, myalgia)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (32%), dyspnea (17%), nasal congestion (11%), upper respiratory tract infection (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (24%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation (3%), anxiety (5%), confusion (3%), delirium (2%), depression (4%), disturbance in attention (3%), drowsiness (3%), insomnia (7%), irritability (3%), memory impairment (4%), myasthenia (10%), sleep disturbance (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Bone fracture (7% to 9%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Dehydration</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pneumonia</p></div>
<div class="block coi drugH1Div" id="F52161044"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer's US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling</i>: Hypersensitivity to larotrectinib or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F52187294"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS effects: Cognitive impairment, mood disorders, dizziness, and sleep disturbance have been reported with larotrectinib. Approximately 40% of patients experienced CNS effects (all grades) and about 4% as grade 3 to 4. Cognitive impairment (including memory impairment, confusion, attention disturbance, delirium, and cognitive disorders) occurred in 11% of patients; symptoms occurred at a median onset of 5.6 months (range: 2 days to 41 months). Grade 3 cognitive impairment requiring dose modification or interruption was reported. Mood disorders and sleep disturbances were reported in 10% to 14% of patients. Mood disorders included anxiety, depression, agitation, and irritability and occurred at a median onset of 3.9 months (range: 1 day to 40.5 months); grade 3 mood disorders occurred rarely. Sleep disturbances included insomnia, somnolence, and sleep disorder; there were no grade 3 or 4 events. Dizziness also occurred in 27% of patients; grade 3 dizziness occurred in 1% of patients. Cognitive impairment, mood disorders, dizziness, and sleep disturbances may require therapy interruption, dose reduction, and/or therapy discontinuation (based on toxicity severity). Caution patients about performing tasks that require mental alertness (eg, operating machinery or driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• Fractures: The risk of skeletal fractures is increased with larotrectinib therapy; fractures occurred more frequently in pediatric patients (9%) than adults (7%) in clinical trials. Most fractures occurred with minimal or moderate trauma. Radiologic abnormalities (possibly indicative of tumor involvement at the site of fracture) were reported in some patients. Most fractures involved the femur, hip, or acetabulum. Promptly evaluate for signs/symptoms of fractures, such as pain, changes in mobility, or deformity. No data are available on larotrectinib effects on healing of confirmed fractures or risk of future fractures.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Hepatotoxicity, including drug-induced liver injury, has been reported. Transaminase increase (of any grade) commonly occurred with larotrectinib; grade 3 AST or ALT elevations were reported; grade 4 ALT elevations occurred rarely. The median time to onset of AST and ALT elevation was 2 months (range: 1 month to 4.3 years for AST elevation and 1 month to 4.2 years for ALT elevation). AST and ALT elevations leading to dose modifications and/or permanent discontinuation have occurred.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-4em;margin-left:6em;">• Appropriate use: Select patients for treatment based on the presence of a neurotrophic tyrosine receptor kinase (NTRK) gene fusion in tumor specimen(s). Information on approved tests is available at <a href="/external-redirect?target_url=http%3A%2F%2Fwww.fda.gov%2Fcompaniondiagnostics&amp;token=SHauxSdf9qNc6lLK16E8IFPiEHUnQ%2FrX%2FFBRnAtp%2BYOOMBGgh36vrA79ff4L%2FMZW&amp;TOPIC_ID=119859" target="_blank">http://www.fda.gov/companiondiagnostics</a>.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878827"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Pediatric patients reported a higher incidence of pyrexia (45% vs 13%) and neutrophil count decrease (60% vs 16%) compared to adults; due to small number of patients studied, it is unknown if reported differences are due to patient age or other factors.</p>
<p style="text-indent:0em;margin-top:2em;">Some dosage forms may contain propylene glycol; in neonates, large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block foc drugH1Div" id="F52187113"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as sulfate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vitrakvi: 25 mg, 100 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral, as sulfate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vitrakvi: 20 mg/mL (100 mL) [contains methylparaben, propylene glycol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vitrakvi: 20 mg/mL (50 mL) [contains sodium benzoate]</p></div>
<div class="block geq drugH1Div" id="F52187111"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F52429891"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Vitrakvi Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $259.90</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $779.70</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Vitrakvi Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg/mL (per mL): $207.91</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F53721527"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as sulfate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vitrakvi: 25 mg, 100 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral, as sulfate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vitrakvi: 20 mg/mL (100 mL) [contains methylparaben, propylene glycol]</p></div>
<div class="block admp drugH1Div" id="F52614692"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer with or without food. If vomiting occurs after dose is administered, do not repeat dose and administer the next dose at the scheduled time.</p>
<p style="text-indent:-2em;margin-left:4em;">Capsule: Swallow whole with water; do not chew or crush capsules.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral solution: Use the provided oral syringe to measure doses; each syringe may be used over a 7-day period; discard after 7 days of use or if damaged, markings illegible, or if it becomes difficult to move the plunger. Do not use a household teaspoon to measure dose (over- or under-dosing may occur). For infants and young children, administer the dose against the inside of the cheek. Following each dose, the syringe should be cleaned; do not boil; see package labeling for detailed cleaning instructions.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed dose: </i>Do not make up the missed dose within 6 hours of the next scheduled dose.</p></div>
<div class="block adm drugH1Div" id="F52187319"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer with or without food. The capsules or oral solution may be used interchangeably.</p>
<p style="text-indent:-2em;margin-left:4em;">Capsules: Swallow capsules whole with water; do not chew or crush capsules.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral solution: Use caution when measuring the oral solution; an oral syringe (provided) should be used when measuring to assure the proper dose is administered. Clean the oral syringe following each dose. See package labeling for detailed cleaning instructions; do not boil. Each oral syringe may be used over a 7-day period; discard after 7 days of use or if oral syringe is damaged, markings are illegible, or if it becomes difficult to move the plunger.</p></div>
<div class="block hazard drugH1Div" id="F52187296"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">This medication is not on the NIOSH (2016) list; however, it may meet the criteria for a hazardous drug. Larotrectinib may cause reproductive toxicity and teratogenicity.</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block sts drugH1Div" id="F52187297"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Capsules: Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F to 86°F).</p>
<p style="text-indent:-2em;margin-left:2em;">Solution: Store at 2°C to 8°C (36°F to 46°F). Do not freeze. Discard unused portion of oral solution 31 days (50 mL) or 90 days (100 mL) after initial opening of the bottle.</p></div>
<div class="block usep drugH1Div" id="F53571517"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of solid tumors that have a neurotrophic receptor tyrosine kinase (<i>NTRK</i>) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment (FDA approved in pediatric patients [age not specified] and adults).</p></div>
<div class="block mst drugH1Div" id="F52187288"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Larotrectinib may be confused with alectinib, entrectinib, lapatinib, lenvatinib, lonafarnib, lorlatinib.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its lists of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F52413197"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of BCRP/ABCG2, CYP3A4 (major), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP3A4 (weak)</p></div>
<div class="block dri drugH1Div" id="F52413194"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">ALPRAZolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ALPRAZolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): CYP3A4 Inhibitors (Weak) may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Larotrectinib. Management: Double the larotrectinib dose if used together with a moderate CYP3A4 inducer. Following discontinuation of the moderate CYP3A4 inducer, resume the previous dose of larotrectinib after a period of 3 to 5 times the inducer's half-life.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Larotrectinib. Management: Avoid use of strong CYP3A4 inducers with larotrectinib. If this combination cannot be avoided, double the larotrectinib dose. Reduced to previous dose after stopping the inducer after a period of 3 to 5 times the inducer's half-life.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Larotrectinib.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Larotrectinib. Management: Avoid use of strong CYP3A4 inhibitors with larotrectinib. If this combination cannot be avoided, reduce the larotrectinib dose by 50%. Increase to previous dose after stopping the inhibitor after a period of 3 to 5 times the inhibitor's half-life.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dofetilide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Finerenone: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Finerenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flibanserin: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Flibanserin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Grapefruit Juice: May increase the serum concentration of Larotrectinib. Management: Avoid use of grapefruit juice with larotrectinib. If this combination cannot be avoided, reduce the larotrectinib dose by 50%. Following discontinuation of grapefruit juice, resume the previous dose of larotrectinib.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Ixabepilone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lemborexant.  Management: The maximum recommended dosage of lemborexant is 5 mg, no more than once per night, when coadministered with weak CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Patients on lomitapide 5 mg/day may continue that dose. Patients taking lomitapide 10 mg/day or more should decrease the lomitapide dose by half. The lomitapide dose may then be titrated up to a max adult dose of 30 mg/day.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lonafarnib: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lonafarnib.  Management: Avoid concurrent use of lonafarnib with weak CYP3A4 inhibitors. If concurrent use is unavoidable, reduce the lonafarnib dose to or continue at a dose of 115 mg/square meter. Monitor for evidence of arrhythmia, syncope, palpitations, or similar effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midazolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Midazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiMODipine: CYP3A4 Inhibitors (Weak) may increase the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of Larotrectinib.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simvastatin: CYP3A4 Inhibitors (Weak) may increase serum concentrations of the active metabolite(s) of Simvastatin. CYP3A4 Inhibitors (Weak) may increase the serum concentration of Simvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Sirolimus (Conventional). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Protein Bound): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Sirolimus (Protein Bound).  Management: Reduce the dose of protein bound sirolimus to 56 mg/m<sup>2</sup> when used concomitantly with a weak CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">St John's Wort: May decrease the serum concentration of Larotrectinib. Management: Avoid use of St John's wort with larotrectinib. If this combination cannot be avoided, double the larotrectinib dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triazolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Triazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Ubrogepant.  Management: In patients taking weak CYP3A4 inhibitors, the initial and second dose (given at least 2 hours later if needed) of ubrogepant should be limited to 50 mg.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F53178890"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Grapefruit may increase larotrectinib plasma levels. Management: Grapefruit or grapefruit juice should be avoided during therapy.</p></div>
<div class="block dic drugH1Div" id="F53178891"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Avoid grapefruit or grapefruit juice during therapy.</p></div>
<div class="block rep_considerations drugH1Div" id="F52187292"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Pregnancy status should be evaluated prior to therapy; females of reproductive potential should use effective contraception during therapy and for 1 week after the final larotrectinib dose. Males with female partners of reproductive potential should also use effective contraception during therapy and for 1 week after the final larotrectinib dose.</p></div>
<div class="block pri drugH1Div" id="F52187291"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based the mechanism of action and available human and animal data, larotrectinib may cause fetal harm if administered to a pregnant female.</p>
<p style="text-indent:0em;margin-top:2em;">Larotrectinib interferes with TRK signaling; obesity, developmental delays, cognitive impairment, insensitivity to pain, and anhidrosis have been observed in persons with congenital mutations in TRK pathway proteins.</p></div>
<div class="block mopp drugH1Div" id="F53571519"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Assess neurotrophic receptor tyrosine kinase (<i>NTRK</i>) gene fusion status in tumor specimen (prior to treatment initiation). Monitor liver function tests (including ALT and AST) every 2 weeks during the first month of treatment, then monthly thereafter, and as clinically indicated; pregnancy test (prior to treatment in patients who can become pregnant). Monitor for neutropenia and signs/symptoms of neurotoxicity. Monitor adherence.</p></div>
<div class="block pha drugH1Div" id="F52187298"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Larotrectinib is a potent and highly selective small-molecule inhibitor of the 3 tropomyosin receptor kinase (TRK) proteins, TRKA, TRKB, and TRKC (Drilon 2018). TRKA, TRKB, and TRKC are encoded by neurotrophic tyrosine receptor kinase (NTRK) genes, NTRK1, NTRK2, and NTRK3. Chromosomal rearrangements involving fusions of NTRK genes may result in constitutively-activated chimeric TRK fusion proteins, acting as an oncogenic driver to promote cell proliferation and survival in tumor cell lines. Larotrectinib has anti-tumor activity in cells with constitutive activation of TRK proteins resulting from gene fusions, deletion of a protein regulatory domain, or in cells with TRK protein overexpression.</p></div>
<div class="block phk drugH1Div" id="F52187299"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: 48 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 70%; to plasma proteins.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic; primarily via CYP3A4; forms an O-linked glucuronide metabolite.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Capsules: 34% (range: 32 to 37%).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 2.9 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: ~1 hour.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (58%; 5% unchanged); Urine (39%; 20% unchanged).</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: 98 L/hour.</p></div>
<div class="block phksp drugH1Div" id="F52187307"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Following oral administration of a single 100 mg larotrectinib dose in subjects with end-stage renal disease (requiring dialysis), the larotrectinib AUC<sub>0-∞</sub> increased 1.5-fold and C<sub>max</sub> increased 1.3-fold, compared to subjects with normal renal function (CrCl ≥90 mL/minute [estimated by Cockcroft-Gault]).</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Larotrectinib clearance is reduced in patients with moderate to severe hepatic impairment (Child-Pugh classes B and C). Following oral administration of a single 100 mg larotrectinib dose, the larotrectinib AUC<sub>0-∞</sub> increased 1.3-fold in subjects with mild impairment (Child-Pugh class A), 2-fold in subjects with moderate impairment (Child-Pugh class B), and 3.2-fold in subjects with severe impairment (Child-Pugh class C), compared to subjects with normal hepatic function. The larotrectinib C<sub>max</sub> increased 1.5-fold in subjects with severe impairment, compared to subjects with normal hepatic function.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F54096819"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Vitrakvi</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Vitrakvi</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Vitrakvi</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Vitrakvi</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Vitrakvi</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Vitrakvi</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Vitrakvi</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Vitrakvi</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Vitrakvi</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Vitrakvi</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Vitrakvi</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Vitrakvi</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Vitrakvi</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Vitrakvi</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Vitrakvi</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Vitrakvi</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Vitrakvi</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Vitrakvi</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Vitrakvi</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Vitrakvi</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Vitrakvi</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Vitrakvi</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Vitrakvi</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Vitrakvi</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Vitrakvi</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Vitrakvi</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Vitrakvi</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Vitrakvi</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Vitrakvi</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Vitrakvi</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Vitrakvi</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  &lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29466156">
<a name="29466156"></a>Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. <i>N Engl J Med</i>. 2018;378(8):731-739.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/larotrectinib-pediatric-drug-information/abstract-text/29466156/pubmed" id="29466156" target="_blank">29466156</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/larotrectinib-pediatric-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/larotrectinib-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/larotrectinib-pediatric-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Accessed November 28, 2018.</div>
</li>
<li>
<div class="reference">
                  Vitrakvi (larotrectinib) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; November 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vitrakvi.2">
<a name="Vitrakvi.2"></a>Vitrakvi (larotrectinib) [product monograph]. Mississauga, Ontario, Canada: Bayer Inc; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/larotrectinib-pediatric-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 119859 Version 123.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
